CClinicalTrials.gg
RecruitingNCT07650136Updated Aug 3, 2026

Method Comparison of Intelligent Fingerprinting Drug Screening System

An observational study in Drug Abuse Illicit, sponsored by Intelligent Bio Solutions Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Intelligent Bio Solutions Inc. · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
144
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Prospective, multi-site, open-label, single- or double-dose, randomized, multi-site performance evaluation of accuracy of the Intelligent Fingerprinting Drug Screening System in the hands of intended users: "operators" and "donors."

Read the detailed description

This will be a study under non-fasting conditions. The total number of healthy adult "operator" subjects (male and non-pregnant females) required for enrollment in this study protocol is nine. The total number of healthy adult "donor" subjects (male and non-pregnant females) required for enrollment in this study protocol is 135. These subjects will be distributed across three sites with the recruiting goal of three operators and 45 subjects per site.

Subjects will be recruited to participate as either "operator" or "donor." The total duration of the study, from check-in through the end of the study will be approximately three days for "operators" with no overnight confinement, and one to eight hours for "donors" at two of the sites. At the third site, 31 "donors" will be dosed twice and will remain at the clinic overnight so that biological sampling can occur 24 hours after the first codeine dose. Because the "operators" are required to be at the clinic for three days, they may be recruited separately and compensated at a different rate than the "donors." "Operators" may be employed by the clinic.

"Donors" at sites 1 and 2 will be block randomized to one of two cohorts: no codeine dose or 60 mg codeine dose. The goal is to complete the study with approximately 69% of subjects in the 60 mg cohort. "Donors" at site 3 will be randomized into one of two cohorts: no codeine dose or two 60 mg doses. The cohort receiving two 60 mg codeine doses will be confined at the clinic overnight to enable additional biological sampling events.

02

Conditions studied

  • Drug Abuse Illicit
03

In context

Lead sponsor

Intelligent Bio Solutions Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

135 "donors" and nine "operators." "Operators" represent end users who utilize the screening system in an office or work setting. These subjects do not have to possess special training in laboratory methods. "Donors" represent end users either applying for employment or working at an organization that conducts pre-employment and/or periodic workplace drug screening.

Sufficient numbers of subjects will be screened to attain those numbers and to ensure that at least 33% of each sex and at least 15% Black subjects are included as "donors" in the study. At least two sites will have both sexes represented among "operator" subjects. Sites may recruit sufficient alternate subjects to ensure achievement of those numbers.

Subjects will be selected from members of the community at large.

Inclusion criteria

1. Able to provide informed consent 2. Completed the screening process within 30 days prior to dosing. 3. Healthy male and non-pregnant female subjects at the time of dosing. 4. Body mass index (BMI) from 18.0 kg/m2 to 32.0 kg/m2, inclusive 5. Weigh at least 60 kg. 5. Females of childbearing potential must be willing to practice an acceptable form of contraception, and have a negative urine pregnancy test on admission to the treatment phase of the study.

6. Males must agree to practice an acceptable form of contraception 7. Judged by the Investigator and/or designee to be in good health as documented by the medical history, and vital sign assessments.

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or unable to provide informed consent.
  2. More than three digits absent from the hands due to congenital or accidental cause(s).
  3. Reports receiving any investigational drug within 30 days prior to dosing.
  4. Reports a clinically significant illness during the 30 days prior to the in-clinic portion of the study (as determined by the Investigator).
  5. Reports any personal history of substance abuse (including drug/alcohol abuse or addiction) or mental illness (e.g. major depression) within one year prior to screening visit.
  6. Is pregnant (females only).
  7. Presence of any clinically significant results from laboratory tests and vital signs assessments, as judged by the Investigator.
  8. Reports history of respiratory depression (e.g., sleep apnea).
  9. Reports history of reaction to codeine (e.g., nausea, allergy).
  10. Current severe hypotension (i.e., systolic blood pressure \<90 mmHg).
  11. Reports known or suspected gastrointestinal obstruction including, paralytic ileus.
  12. Reports current presence of acute bronchial asthma/ upper airway obstruction.
  13. Reports a history of clinically significant allergies, including food or drug allergies, as judged by the Investigator.
  14. Reports history or current condition of adrenal insufficiency.
  15. Reports history or current condition of renal disease.
  16. If, in the opinion of the Investigator, the subject is not suitable for the study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
144 participants (estimated)
Patient registry
No

Groups and cohorts

  • Undosed

    No codeine administered

  • Dosed

    2 doses of codeine administered in tablet form, 60 mg per dose

06

What researchers measure

Primary outcomes

  1. Sensitivity

    Sensitivity of the Intelligent Fingerprinting DSC 7-Plus Drug Screening Cartridge for Codeine

    Time frame: 24 hrs

  2. Specificity

    Specificity of the Intelligent Fingerprinting DSC 7-Plus Drug Screening Cartridge for Codeine

    Time frame: 24 hrs

  3. Accuracy

    Accuracy of the Intelligent Fingerprinting DSC 7-Plus Drug Screening Cartridge for Codeine

    Time frame: 24 hrs

07

Study locations

1 of 1 sites recruiting
  • CenExel Clinical Research
    Marlton, New Jersey 08053, United States
    • Elan Cohen, PhD · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07650136
Lead sponsor
Intelligent Bio Solutions Inc.
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Jun 2, 2026
Primary completion
Jul 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Aug 3, 2026

Study contacts

Elan Cohen, PhD
Contact
e.cohen@cenexel.com
856.452.9901

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion